Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 6 | 2023 | 1502 | 1.630 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 128 | 0.990 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2021 | 807 | 0.740 |
Why?
|
| Estrogen Receptor alpha | 1 | 2019 | 111 | 0.640 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 187 | 0.630 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 628 | 0.600 |
Why?
|
| Menstrual Cycle | 1 | 2015 | 35 | 0.530 |
Why?
|
| Endometrial Neoplasms | 1 | 2015 | 66 | 0.490 |
Why?
|
| DNA Methylation | 4 | 2019 | 325 | 0.490 |
Why?
|
| Prognosis | 5 | 2021 | 739 | 0.450 |
Why?
|
| DNA Repair | 2 | 2024 | 188 | 0.400 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 2 | 2021 | 9 | 0.370 |
Why?
|
| Female | 13 | 2024 | 20969 | 0.340 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 441 | 0.330 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 113 | 0.330 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2021 | 145 | 0.330 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 190 | 0.310 |
Why?
|
| Humans | 15 | 2024 | 37093 | 0.270 |
Why?
|
| Survival Analysis | 2 | 2023 | 325 | 0.260 |
Why?
|
| Ovarian Neoplasms | 2 | 2021 | 312 | 0.260 |
Why?
|
| Aged | 6 | 2021 | 6741 | 0.260 |
Why?
|
| Middle Aged | 8 | 2024 | 10129 | 0.260 |
Why?
|
| Gene Expression | 2 | 2019 | 674 | 0.240 |
Why?
|
| Germ-Line Mutation | 1 | 2024 | 57 | 0.240 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2024 | 75 | 0.230 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 275 | 0.230 |
Why?
|
| Calcium Signaling | 1 | 2024 | 101 | 0.230 |
Why?
|
| Cluster Analysis | 1 | 2023 | 195 | 0.220 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2024 | 194 | 0.210 |
Why?
|
| Mesothelioma | 1 | 2024 | 144 | 0.210 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 2231 | 0.210 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2021 | 10 | 0.210 |
Why?
|
| Fanconi Anemia | 1 | 2021 | 12 | 0.200 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2019 | 63 | 0.200 |
Why?
|
| Databases, Genetic | 2 | 2019 | 93 | 0.200 |
Why?
|
| Cyanobacteria | 1 | 2021 | 23 | 0.200 |
Why?
|
| Mouth | 1 | 2021 | 45 | 0.200 |
Why?
|
| Receptors, Calcitriol | 1 | 2021 | 69 | 0.180 |
Why?
|
| Adult | 6 | 2023 | 11712 | 0.170 |
Why?
|
| eIF-2 Kinase | 1 | 2019 | 14 | 0.170 |
Why?
|
| DNA Damage | 1 | 2021 | 352 | 0.170 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2019 | 15 | 0.170 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 2379 | 0.160 |
Why?
|
| Tamoxifen | 1 | 2019 | 65 | 0.160 |
Why?
|
| Up-Regulation | 1 | 2021 | 513 | 0.160 |
Why?
|
| Colitis | 1 | 2019 | 65 | 0.160 |
Why?
|
| CpG Islands | 1 | 2018 | 97 | 0.160 |
Why?
|
| Polyadenylation | 1 | 2018 | 49 | 0.150 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 172 | 0.150 |
Why?
|
| Receptors, Estrogen | 1 | 2018 | 156 | 0.150 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 4 | 0.140 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 186 | 0.140 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2016 | 15 | 0.140 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2016 | 18 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2018 | 534 | 0.140 |
Why?
|
| Signal Transduction | 3 | 2021 | 1908 | 0.140 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 40 | 0.140 |
Why?
|
| NF-kappa B | 1 | 2019 | 339 | 0.140 |
Why?
|
| Phosphorylation | 1 | 2019 | 928 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 643 | 0.130 |
Why?
|
| Disease Progression | 1 | 2018 | 601 | 0.130 |
Why?
|
| Risk Factors | 3 | 2021 | 3562 | 0.130 |
Why?
|
| Genetic Markers | 1 | 2015 | 142 | 0.130 |
Why?
|
| Estrogens | 1 | 2015 | 202 | 0.120 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 409 | 0.110 |
Why?
|
| Genotype | 1 | 2015 | 730 | 0.110 |
Why?
|
| Genomic Instability | 2 | 2024 | 38 | 0.110 |
Why?
|
| Phenotype | 1 | 2015 | 689 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 767 | 0.100 |
Why?
|
| Mice | 2 | 2019 | 5913 | 0.100 |
Why?
|
| Neoplasms | 1 | 2018 | 1103 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1130 | 0.080 |
Why?
|
| Child | 1 | 2015 | 3131 | 0.070 |
Why?
|
| Male | 5 | 2024 | 20025 | 0.070 |
Why?
|
| Animals | 2 | 2019 | 15081 | 0.060 |
Why?
|
| Adolescent | 1 | 2015 | 5363 | 0.060 |
Why?
|
| Asbestos | 1 | 2024 | 55 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2024 | 272 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2024 | 213 | 0.050 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2021 | 21 | 0.050 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2021 | 12 | 0.050 |
Why?
|
| beta Catenin | 1 | 2021 | 48 | 0.050 |
Why?
|
| DNA Replication | 1 | 2021 | 152 | 0.050 |
Why?
|
| Connecticut | 1 | 2020 | 14 | 0.050 |
Why?
|
| New Jersey | 1 | 2020 | 15 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 251 | 0.040 |
Why?
|
| Interleukin-16 | 1 | 2019 | 5 | 0.040 |
Why?
|
| New York City | 1 | 2020 | 220 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 60 | 0.040 |
Why?
|
| Base Sequence | 1 | 2021 | 997 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 139 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 212 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2020 | 125 | 0.040 |
Why?
|
| Life Style | 1 | 2020 | 308 | 0.040 |
Why?
|
| Cell Movement | 1 | 2021 | 571 | 0.040 |
Why?
|
| Models, Biological | 1 | 2021 | 677 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 562 | 0.040 |
Why?
|
| Histones | 1 | 2018 | 190 | 0.040 |
Why?
|
| Incidence | 1 | 2020 | 922 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2019 | 435 | 0.040 |
Why?
|
| Apoptosis | 1 | 2024 | 1398 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 893 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2019 | 933 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2015 | 17 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2015 | 75 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1198 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 190 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 623 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 485 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 1609 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 1371 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 515 | 0.030 |
Why?
|
| Obesity | 1 | 2020 | 1067 | 0.020 |
Why?
|
| United States | 1 | 2021 | 4223 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 4268 | 0.020 |
Why?
|